bupropion has been researched along with Panic Disorder in 6 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite anecdotal reports suggesting that bupropion may be effective for panic disorder, both clinical lore and the results of one small controlled study suggest otherwise." | 9.10 | Bupropion sustained release for panic disorder. ( Ballenger, J; Emmanuel, N; Farach, FJ; Kinrys, G; Korbly, NB; Pollack, MH; Simon, NM; Worthington, JJ, 2003) |
| "We report on a 57-year-old woman, diagnosed with Parkinson's disease, whose panic disorder showed marked improvement after introduction of bupropion, a norepinephrine-dopamine reuptake inhibitor." | 7.74 | Treatment of panic disorder with bupropion in a patient with Parkinson's disease. ( Bäcker, A; Gebhardt, S; Krieg, JC; Röttgers, H; Schu, U, 2008) |
| "Despite anecdotal reports suggesting that bupropion may be effective for panic disorder, both clinical lore and the results of one small controlled study suggest otherwise." | 5.10 | Bupropion sustained release for panic disorder. ( Ballenger, J; Emmanuel, N; Farach, FJ; Kinrys, G; Korbly, NB; Pollack, MH; Simon, NM; Worthington, JJ, 2003) |
| "We report on a 57-year-old woman, diagnosed with Parkinson's disease, whose panic disorder showed marked improvement after introduction of bupropion, a norepinephrine-dopamine reuptake inhibitor." | 3.74 | Treatment of panic disorder with bupropion in a patient with Parkinson's disease. ( Bäcker, A; Gebhardt, S; Krieg, JC; Röttgers, H; Schu, U, 2008) |
| "The pharmacologic treatment of panic disorder is aimed at reducing or eliminating panic attacks, avoidance behavior, anticipatory anxiety, and comorbid conditions--and substantially improving and normalizing overall function and quality of life." | 1.33 | The pharmacotherapy of panic disorder. ( Pollack, MH, 2005) |
| "With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy." | 1.30 | Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. ( Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gebhardt, S | 1 |
| Röttgers, H | 1 |
| Bäcker, A | 1 |
| Schu, U | 1 |
| Krieg, JC | 1 |
| Serafini, G | 1 |
| Pompili, M | 1 |
| Fusar-Poli, P | 1 |
| Porfiri, G | 1 |
| Giordano, G | 1 |
| Ferracuti, S | 1 |
| Girardi, P | 1 |
| Tatarelli, R | 1 |
| Simon, NM | 1 |
| Emmanuel, N | 1 |
| Ballenger, J | 1 |
| Worthington, JJ | 1 |
| Kinrys, G | 1 |
| Korbly, NB | 1 |
| Farach, FJ | 1 |
| Pollack, MH | 2 |
| Young, SJ | 1 |
| Bodkin, JA | 1 |
| Lasser, RA | 1 |
| Wines, JD | 1 |
| Gardner, DM | 1 |
| Baldessarini, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder[NCT00438971] | Phase 4 | 15 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The BAI is a 21-item self-report measure of anxiety with a focus on somatic symptoms. Total scores range from 0 to 63, with higher scores reflecting greater symptom severity. (NCT00438971)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 14.7 |
The CGI-S is a clinician-rated instrument used to assess global severity of symptoms. The CGI-S ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill). Remission was defined strictly as a CGI-S score of 1 or 2 (not at all ill or borderline ill) and zero panic attacks at endpoint. (NCT00438971)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 3.47 |
The LIFE-RIFT is a brief measure of psychosocial functioning in work, interpersonal relations, satisfaction, and recreation. Scores on the LIFE-RIFT can range from 4, indicating very good functioning (no impairment) in all of the 4 component areas, to 20, indicating very poor functioning (severe impairment) in all of the 4 areas. (NCT00438971)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 9.33 |
The MADRS is a 10-item clinician rating of depressive symptoms. Scores range from 0 to 60, with higher scores reflecting greater symptom severity. (NCT00438971)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 9.07 |
The PAS is a measure that assesses participants' total number of panic attacks (situational and unexpected with full and limited symptoms), as well as anticipatory anxiety, since last visit. There is no total score. (NCT00438971)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 0.90 |
The PDSS contains seven items assessing multiple dimensions of panic disorder severity, including (a) frequency of panic attacks, (b) distress during panic attacks, (c) anticipatory anxiety, (d) agoraphobic fear and avoidance, (e) interoceptive fear and avoidance, (f) impairment of work functioning, and (g) impairment of social functioning. The PDSS ranges from 0 to 28, with higher ratings reflecting greater degrees of symptom severity. (NCT00438971)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 9.13 |
The Q-LES-Q is a self-report measure of the degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning. Only the first 14 items are included in scoring, which ranges from 14 to 70, with higher scores reflecting greater enjoyment and satisfaction. The last two items are not included in the total score but are standalone items. (NCT00438971)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 49.3 |
The SDS is a 3-item measure with each item rated on a 10-point scale. The SDS measures the extent to which work/school, social life, and home life or family responsibilities are impaired by symptoms. Total scores range from 0 to 30, with higher scores reflecting greater impairment. (NCT00438971)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 9.40 |
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
1 review available for bupropion and Panic Disorder
| Article | Year |
|---|---|
Bupropion and panic disorder: case report and review of the literature.
Topics: Bupropion; Dopamine Uptake Inhibitors; Humans; Male; Middle Aged; Panic Disorder | 2011 |
1 trial available for bupropion and Panic Disorder
| Article | Year |
|---|---|
Bupropion sustained release for panic disorder.
Topics: Adult; Bupropion; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders | 2003 |
4 other studies available for bupropion and Panic Disorder
| Article | Year |
|---|---|
Treatment of panic disorder with bupropion in a patient with Parkinson's disease.
Topics: Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Female; Humans; Middle Aged; Pani | 2008 |
The pharmacotherapy of panic disorder.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bupropion; Humans; Long-Term Care; Monoamin | 2005 |
Panic associated with combining fluoxetine and bupropion.
Topics: Adult; Bupropion; Depressive Disorder; Dopamine Uptake Inhibitors; Drug Administration Schedule; Dru | 1996 |
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Depressive Disorder; Dr | 1997 |